目的:这项研究估计了斯洛伐克COVID-19患者的谵妄发生率,探讨治疗关联,并检查对住院率和死亡率的影响.
背景:由SARS-CoV-2引起的COVID-19大流行严重影响了全球健康。谵妄,一种严重的急性脑功能障碍,常见于住院患者,包括那些患有COVID-19的人。
方法:一项回顾性研究分析了Kosice474例确诊为SARS-CoV-2感染的住院患者的数据,斯洛伐克。使用标准化ICD-10标准诊断谵妄。统计分析检查了谵妄,精神症状,治疗方式,住院时间,和死亡率。
结果:29.54%(140例患者)出现谵妄。失眠,焦虑,谵妄是普遍存在的精神症状。谵妄患者失眠程度较高,焦虑,嗜睡,激动,侵略率。高流量鼻腔吸氧等治疗方法,糖皮质激素,抗生素,和anakinra与较高的谵妄发生率相关。谵妄更常见于抗精神病药的使用(tiapride,喹硫平,氟哌啶醇),而西酞普兰似乎有保护作用。没有发现与死亡率的显著关联。使用苯二氮卓类药物的患者,催眠药,或者tiapride住院时间更长。
结论:这项研究提供了对斯洛伐克COVID-19患者谵妄发生率的见解,治疗协会,以及管理精神症状和治疗选择以获得最佳结果的重要性(表。6,参考。33).
OBJECTIVE: This study estimated delirium incidence in Slovak COVID-19 patients, explored treatment associations and examined the impact on hospitalization and mortality.
BACKGROUND: The COVID-19 pandemic caused by SARS-CoV-2 has significantly affected global health. Delirium, a severe form of acute brain dysfunction, is common in hospitalized patients, including those with COVID-19.
METHODS: A retrospective study analyzed data from 474 hospitalized patients with confirmed SARS-CoV-2 infection in Kosice, Slovakia. Delirium was diagnosed using standardized ICD-10 criteria. Statistical analyses examined associations between delirium, psychiatric symptoms, treatment modalities, hospitalization duration, and mortality.
RESULTS: 29.54 % (140 patients) had delirium. Insomnia, anxiety, and delirium were prevalent psychiatric symptoms. Delirium patients had higher insomnia, anxiety, somnolence, agitation, and aggression rates. Treatments like high-flow nasal oxygen, glucocorticoids, antibiotics, and anakinra were associated with higher delirium incidence. Delirium was more common with antipsychotic use (tiapride, quetiapine, haloperidol), while citalopram seemed protective. No significant associations were found with mortality. Patients using benzodiazepines, hypnotics, or tiapride had longer hospital stays.
CONCLUSIONS: This study provides insights into delirium incidence in Slovak COVID-19 patients, treatment associations, and the importance of managing psychiatric symptoms and treatment choices for optimal outcomes (Tab. 6, Ref. 33).